Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Cash from Financing Activities (2020 - 2025)

Historic Cash from Financing Activities for Xeris Biopharma Holdings (XERS) over the last 6 years, with Q3 2025 value amounting to $13.8 million.

  • Xeris Biopharma Holdings' Cash from Financing Activities rose 1678674.7% to $13.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.1 million, marking a year-over-year decrease of 6510.02%. This contributed to the annual value of $36.2 million for FY2024, which is 234228.15% up from last year.
  • According to the latest figures from Q3 2025, Xeris Biopharma Holdings' Cash from Financing Activities is $13.8 million, which was up 1678674.7% from $942000.0 recorded in Q2 2025.
  • Xeris Biopharma Holdings' Cash from Financing Activities' 5-year high stood at $78.2 million during Q1 2022, with a 5-year trough of -$3.1 million in Q1 2025.
  • Moreover, its 5-year median value for Cash from Financing Activities was $398000.0 (2024), whereas its average is $10.6 million.
  • The largest annual percentage gain for Xeris Biopharma Holdings' Cash from Financing Activities in the last 5 years was 3922480.0% (2022), contrasted with its biggest fall of 1880000.0% (2022).
  • Quarter analysis of 5 years shows Xeris Biopharma Holdings' Cash from Financing Activities stood at $125000.0 in 2021, then skyrocketed by 39224.8% to $49.2 million in 2022, then tumbled by 102.51% to -$1.2 million in 2023, then skyrocketed by 132.25% to $398000.0 in 2024, then skyrocketed by 3379.9% to $13.8 million in 2025.
  • Its Cash from Financing Activities stands at $13.8 million for Q3 2025, versus $942000.0 for Q2 2025 and -$3.1 million for Q1 2025.